You are here

Home › FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound › FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound

FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound

Primary tabs

FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound

Fri, 2022-08-19 16:38 — mike kraft
FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound The U.S. Food and Drug Administration (FDA) has ordered Pfizer Inc to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday. Reuters Reuters

...

Pfizer is "working with the FDA to finalize a protocol to study patients who may be in need of retreatment," and will provide details when available, a company spokesperson said.

Country / Region Tags: 
United States
General Topic Tags: 
COVID-19
Treatments
Disease
Disease Prevention
Government
Health
Medical Testing
Mutations
Pandemics
Public Health
Research
Problem, Solution, SitRep, or ?: 
Situation Report
Groups this Group Post belongs to: 
Global Health
Medical - global
- Private group -
Workflow history
Revision ID Field name Date Old state New state name By Comment Operations
No state No state
howdy folks